Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

Brexit: What Can The Life Sciences Industry Do About It?

With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.

Brexit United Kingdom Strategy

EMA Bidders, An Infographic On The Runners And Riders

Denmark, France, Ireland, Italy, Spain and Sweden have all have expressed a keen interest in hosting the European Medicines Agency once the UK leaves the EU. Bids are expected to be made sometime early next year, probably once the UK government triggers Article 50. There is at present no formal process for allocating an agency to a particular EU country, as this tends to be done via a process of political wrangling, so each prospective candidate will need to garner as much support for their bid as possible from the other member states.

Europe Brexit Policy & Regulation

Latest From Brexit

Ipsen Promotes UK Business; Kidney Cancer Drug Gets NICE Nod

Ipsen's VP of commercial operations for the UK and Ireland outlines how the French company will use managed access programs to get drugs reimbursed on the NHS and describes Ipsen's plans for growth and greater investment in the UK, despite Brexit uncertainties.

Business Strategies Brexit

BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors

In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.

Deals Business Strategies

Stability Or Chaos? UK Election Result Increases The Uncertainty For Pharma

UK industry bodies have expressed concern over the result of the UK general election, as the prime minister decides to form a minority government and EU officials say Brexit talks could be delayed.

United Kingdom Brexit

First UK Debt Financing Fund For Life Sciences Raises $762m

The first life sciences-focused specialized investment fund, BioPharma Credit, has completed an IPO in London, lifting the spirits of the investment community pondering the long-term consequences of the country withdrawing from the EU.

Financing Brexit

Brexit And International Reference Pricing To Cost Companies Billions Of Dollars

Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.

Brexit Market Access

Europe's Pharma Tries To 'Keep Calm And Carry On' Amid Storm Strikes

Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.

Europe Brexit
See All